Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 16, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them (PCA), rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain consolidated financial statements.
Material Changes and Transaction Details
The filing discloses two specific transactions involving GSK American Depositary Shares (ADSs) on August 12, 2016:
- Dr. M M Slaoui (Chairman, Global Vaccines): Acquired an increase of 14 ADSs at a price of $44.17 per ADS.
- Dr. K Slaoui (PCA of Dr. M M Slaoui): Acquired an increase of 2 ADSs at a price of $44.17 per ADS.
Nature of Transaction: Both transactions resulted from the notional allocation of ADSs due to the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned share allocations.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr. M M Slaoui and Dr. K Slaoui following these allocations.
- Confirm the market price of GSK ADSs on August 12, 2016, to validate the transaction price of $44.17.
- Review the GSK 401(K) plan rules regarding notional allocations and revaluation mechanisms.
- Check for any other concurrent insider trading filings for the same period.